Abstract Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity
26.00 43.50 38.50 Our friendly and experienced team are ready in store and over the phone to help answer your questions, offer hints and tips and help choose the right products for you.
This section covers what to expect after your first month, during dose escalation, at your maintenance dose, and when considering whether to continue or taper your treatment
Infant Child Dev 20:35-46
Trials and post-market surveillance identified risks in specific populations, such as those with a history of medullary thyroid cancer, pancreatitis, or severe kidney disease, and screening for those risks is not possible in an over-the-counter setting
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
.png)
